October 18, 2017 07:18 AM EDT

Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines

Eli Lilly is diving into the messenger RNA arena, signing off on a heavily back-ended $1.8 billion deal with Germany’s CureVac to develop up to …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lil­ly is mak­ing a $1.8B leap in­to the mR­NA field, tar­get­ing next-gen can­cer vac­cines